Pharmena   Report issue

For profit Phase 1
Founded: Lodz Poland (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2007
NCT00685737
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (3)

1-mna (1 trial)

niacin (1 trial)

n-methylnicotinamide chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperlipidemias (Phase 1)

Hyperlipoproteinemias (Phase 1)

Malnutrition (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3